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a  b  s  t  r  a  c  t
We  performed a systematic review to evaluate the efﬁcacy and safety of inﬂix-
imab + methotrexate (IFX + MTX) regimens versus MTX alone or in combination with other
disease-modifying anti-rheumatic drugs (DMARDs). We searched through major databases,
the grey literature and did a manual search. Two independent reviewers conducted the selec-
tion,  data extraction and analysis of the quality of the studies. Meta-analysis was conducted
using Review Manager® 5.1 software. Nine trials were included. The mean modiﬁed Jadad
score was 4.4, but only one study showed low risk of bias. IFX + MTX regimen presented
better responses in clinical outcomes of ACR and DAS28 by up to 54 weeks, and of radio-
graphic progression by up to 104 weeks. Withdrawals due to lack of efﬁcacy was  lower in the
IFX + MTX group. No signiﬁcant difference in adverse events was observed. The IFX + MTX
combination is more effective than treatment with MTX alone or DMARDs combination. This
regimen presented good tolerability in patients previously treated with DMARDs, not treated
with  MTX or with insufﬁcient responses to MTX. The efﬁcacy of IFX + MTX is noted primarily
during initial periods of treatment. High doses of IFX were as effective as the standard dose,
but  with possible higher risk of serious infections. Therefore, we  advise clinicians to use thestandard dose of IFX 3 mg/kg every 8 weeks.
© 2014 Elsevier Editora Ltda. All rights reserved.
 Institution: School of Medicine, UFMG, Belo Horizonte, MG, Brazil.
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Inﬂiximabe,  metotrexato  e  sua  combinac¸ão  no  tratamento  da  artrite
reumatoide:  revisão  sistemática  e  metanálise
Palavras-chave:
Inﬂiximabe
Revisão sistemática
Metanálise
Artrite reumatoide
Eﬁcácia
r  e  s  u  m  o
Foi feita uma revisão sistemática para avaliar a eﬁcácia e a seguranc¸a do esquema inﬂix-
imabe + metotrexato (IFX + MTX) versus MTX isoladamente ou em combinac¸ão com outros
medicamentos modiﬁcadores do curso da doenc¸a (MMCD). Pesquisou-se nas principais
bases de dados eletrônicas e na literatura cinzenta e fez-se uma busca manual. Dois
revisores independentes ﬁzeram a selec¸ão, extrac¸ão de dados e análise da qualidade dos
estudos. A metanálise foi feita com o software Review Manager® 5.1. Incluíram-se nove
estudos. O escore médio na escala de Jadad modiﬁcada foi de 4,4, mas somente um estudo
mostrou baixo risco de viés. O esquema IFX + MTX apresentou melhores respostas nos
desfechos clínicos do escore ACR e do DAS28 por até 54 semanas e na progressão radio-
gráﬁca por até 104 semanas. Os abandonos decorrentes da falta de eﬁcácia foram menores
no  grupo IFX + MTX. Não foi observada diferenc¸a estatisticamente signiﬁcante nos eventos
adversos. A combinac¸ão IFX + MTX é mais eﬁcaz do que o tratamento com MTX  isolado
ou  em combinac¸ão com MMCD. Esse esquema apresentou boa tolerabilidade em pacientes
previamente tratados com MMCD, não tratados com MTX ou com respostas insuﬁcientes
ao  MTX. A eﬁcácia do regime IFX + MTX é observada principalmente durante os períodos
iniciais do tratamento. Altas doses de IFX foram tão eﬁcazes quanto a dose padrão, mas
com a possibilidade de “um” maior risco de infecc¸ões graves. Recomenda-se, portanto, que
os  médicos utilizem a dose padrão de IFX de 3 mg/kg a cada oito semanas.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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and LILACS (until October 2012) databases. Different combi-ntroduction
heumatoid arthritis (RA) is an autoimmune disease charac-
erised by peripheral, symmetric polyarthritis with potential
or joint deformity that can cause functional disability, prema-
ure mortality and reduced quality of life. It is estimated that
.3–1.0% of the population worldwide is affected by RA, which
s most frequently observed in developing countries and in
omen.1
The treatment of RA patients combines educational, pre-
entive and non-pharmacological interventions with pharma-
ological treatment and surgical procedures. First-line therapy
ncludes the early use of a synthetic disease-modifying
nti-rheumatic drug (DMARD), such as methotrexate (MTX),
hich is the drug of choice.2 However, only 20–40% MTX
onotherapy-treated patients show a satisfactory clinical
esponse.3 Drug combinations are a valid strategy in non-
esponsive patients, which may include the addition of
nother synthetic DMARD or the biological DMARD agents,
uch as tumour necrosis factor  blockers (anti-TNF).4 Inﬂix-
mab  (IFX) is a chimeric monoclonal antibody (murine) of the
nti-TNF class that represents approximately 40% of biolog-
cal agent prescriptions.5,6
Second-line treatment strategies show similar rates of suc-
ess and the choice among them is based primarily on the
resence or absence of a poor prognosis and in the dis-
ase activity.4,7 The beneﬁts of adding sulfasalazine (SSZ) and
ydroxychloroquine (HCQ),8–11 leﬂunomide12 or cyclosporin13o MTX  therapy have been demonstrated. The IFX + MTX
ombination has been assessed in numerous systematic
eviews14–19 but their control groups included only placeboor MTX  treatment. Key issues, including the effect of dis-
ease duration, dose and patient proﬁle, were not sufﬁciently
addressed in most of these reviews.
With this systematic review and meta-analysis we  aimed to
assess the efﬁcacy and safety of IFX + MTX  compared to MTX  in
monotherapy or in combination with other synthetic DMARDs
considering treatment-relevant clinical outcomes.
Methods
A systematic review with meta-analysis was performed
according to the Cochrane Handbook for Systematic Reviews
of Interventions. The results were reported according to the
“Preferred Reporting Items for Systematic Reviews and Meta
Analyses: The PRISMA statement”.20 This review is part of
another project entitled “Evaluation of the effectiveness and
safety of biological agents adalimumab, etanercept, inﬂiximab
and rituximab used in the treatment of rheumatoid arthritis,
psoriatic arthritis and ankylosing spondylitis, Brazil and Minas
Gerais”, which was performed by the Research Group on Phar-
macoepidemiology and Research Group on Health Economics
at the UFMG.
Search  strategy
The online search was performed in EMBASE (until April
2012), CENTRAL (until June 2012), PubMed (until July 2012)nations of keywords, mesh terms and ﬁlters were applied,
and the full search strategy for each database was provided
online in Appendix 1. We  performed a manual search in the
 o l . 2148  r e v b r a s r e u m a t
references of all included studies and previously published
systematic reviews. We  also searched the grey literature in the
Annals of the American College of Rheumatology (ACR, 2011,
2012), the European League Against Rheumatism (EULAR,
2010–2012) meetings and the thesis and dissertation databases
of the Coordination for the Improvement of Higher Education
Personnel, Brazilian Digital Library of Theses and Disserta-
tions, the Digital Library of Theses and Dissertations of USP
and the ProQuest Dissertation and Theses Database. Ongoing
Randomised Clinical Trials (RCT) were surveyed in the Interna-
tional Clinical Trials Registry Platform Search Portal, Brazilian
Registry of Clinical Trials and at clinicaltrials.gov.
Eligibility  criteria
We  included phase III RCTs that evaluated RA patients diag-
nosed according to the American College of Rheumatology
(ACR) criteria 198721 regardless of disease duration. We con-
sidered eligible studies comparing IFX + MTX versus MTX
as a monotherapy or in combination with other synthetic
DMARDs. The minimal follow-up period was two months.
The following exclusion criteria were applied: studies that
were not performed exclusively on RA patients; changes in
therapy over time; drug-conversion studies; pilot studies; edi-
torials/reviews/letters/comments; and studies published in
languages other than Portuguese, Spanish or English.
Study  selection
Two reviewers independently evaluated the titles, abstracts
and full text of all identiﬁed studies to assess their eligibility.
A third reviewer resolved disagreements.
Assessment  of  methodological  quality  and  risk  of  bias
Methodological quality was assessed using the modiﬁed Jadad
scale,22 which evaluates randomisation, blinding and loss to
follow-up using seven dichotomous questions that are worth
one point each. Studies with inadequate randomisation lose
one point. The ﬁnal score ranges from 0 to 6: 0–2 indicate a
low-quality study, 3 or 4 indicates adequate quality, and 5 or
6 indicates high quality. The risk of bias was assessed using
the Cochrane Collaboration tool,23 which considers six dimen-
sions: random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of outcome
assessment, incomplete outcome data and selective reporting
of outcomes. The study was classiﬁed as having low risk of bias
when all criteria were reported and were adequate, a high risk
of bias when at least one of the criteria was inadequate, and
an uncertain risk of bias when one or more  items were not
reported. The inter-rater reliability was measured using the
Kappa statistic according to Landis and Kock24 and calculated
using SPSS® 17.0 software. Inter-rater reliability was substan-
tial for the modiﬁed Jadad scale (0.70 ± DP 0.73) and moderate
for the risk of bias assessment (0.55 ± 0.78).Data  collection
Two independent reviewers collected data on study design,
methodological quality, risk of bias, patient proﬁle, efﬁcacy 0 1 5;5 5(2):146–158
and safety outcomes using an electronic form that was
designed in Excel® 2007. A consensus resolved all disagree-
ments.
The primary outcome was the measurement of ACR20,
which is deﬁned as 20% improvement in swollen joints
and joint pain in combination with a 20% improvement in
three of ﬁve criteria: patient’s global assessment of pain;
patient’s global assessment of disease activity; physician’s
global assessment of disease activity; patient’s assessment of
physical function; and C-reactive protein levels.25 Secondary
outcomes included the ACR50 and ACR70, clinical remission
(deﬁned as a DAS28 [Disease Activity Score 28] < 2.6), radio-
graphic data, loss to follow-up and adverse events.
Statistical  analysis
A random effects model was used for all meta-analyses due
to the clinical heterogeneity of the included studies. Rela-
tive risk (RR) was used as a measure of treatment effect,
and it was calculated using the Mantel–Haenszel method
for binary data. Mean differences and the inverse variance
method were used for continuous data. Conﬁdence intervals
of 95% were presented for both measures. Heterogeneity was
assessed using the 2 test for heterogeneity and the I2 index
and was considered statistically signiﬁcant when p value was
lower than 0.10 and I2 value higher than 40%.26 We  identiﬁed
the source of heterogeneity through a sensitivity analysis, in
which studies were removed from the meta-analysis one by
one to investigate possible causes related to patients and study
characteristics. Subgroup analysis was also performed to eval-
uate the effects of pre-treatment, study length, dosage and the
IFX administration regimen. In the meta-analysis we included
results from the longest available follow-up, unless indicated
otherwise. We used Review Manager® software version 5.1
for statistical tests (Copenhagen: The Cochrane Collaboration,
2011).
Results
We identiﬁed 5782 articles, of which 249 were considered for
full reading and 74 articles were selected. A total of 11 articles,
representing multiple publications of nine studies, evaluated
IFX and met  the inclusion criteria for this review (Fig. 1). We
found one completed phase III clinical trial with unpublished
results (Table 1, online resource). We  have not found any the-
sis or dissertations. Abstracts found in the annals of meetings
had their respective full articles collected by manual search.
The characteristics of the nine included trials are presented
in Table 1. The studies were published between 1998 and
2012, and the follow-up periods ranged from 14 to 104 weeks.
Patients proﬁle included individuals previously treated with
DMARDs, not treated with MTX or those that had insufﬁcient
responses to MTX.
Most studies deﬁned active RA by the presence of six
or more  swollen joints and six or more  tender joints in
combination with the additional criteria of morning stiff-
ness, C-reactive protein levels and erythrocyte sedimentation
rates. ASPIRE27 and ATTEST28 deﬁned active RA as 10 or
more  swollen joints and 12 or more  tender joints. Zhang29
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Records identified throught
database searching: 5782
Manual search: 9
Excluded
duplicates: 92
(2648) excluded based on:
Records sereened on basis
of abstract: 3051
Records screened on basis
of full text: 249
Total records included: 74
Other biologics: 63 publications
Infliximabe: 11 publications, 9 RCTs
(175) excluded based on:
Records screened on basis
of title: 5699
(1912) excluded based on:
Records identified throught
systematic literature
search: 5791
PubMed: 3620
Lilacs: 98
Embase: 1577
Central:487
Type of study: 1123
Type of participant: 283
Type of intervention: 135
Outcome not evaluated: 1107
Type of study: 2256
Type of participant: 79
Type of intervention: 83
Outcome not evaluated: 384
Type of study: 96
Type of participant: 02
Type of intervention: 13
Outcome not evaluated: 24
Not available: 40
Fig. 1 – Diagram of included studies.
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Table 1 – Population baseline characteristics of the included studies.
Study – follow-up Patients Age (years) Duration of Number of Number of Number of Patients on oral Patients on
(n) mean (SD) disease (years) previous DMARD swollen joints tender joints steroid therapy NSAID therapy
mean (SD) mean (SD) mean (SD) mean (SD) % %
Maini et al.33 – 26 weeks
Placebo + MTX 14 48.8 (12.3) 7.6 (4) 2 (1–3)b 17 (12–25)b 28 (22–47)b 50 NI
IFX IV 3 mg/kg each 4 weeks + MTX 15 58.9 (10) 12.1 (9) 2 (2–4)b 16 (13–22)b 21 (12–31)b 60 NI
IFX IV 3 mg/kg each 4 weeks 14 47 (15) 7.8 (4.3) 2.5 (2–3)b 17 (11–32)b 31 (23–39)b 50 NI
IFX IV 10 mg/kg each 4 weeks + MTX 14 50.4 (13.4) 11.1 (7.4) 2  (2–4) 20 (14–31)b 26 (23–37)b 28 NI
IFX IV 10 mg/kg each 4 weeks 15 56.3 (9.1) 9.7 (7.4) 2 (1–4) 19 (11–22)b 23 (16–35)b 60 NI
ATTRACT35,36 – 30 weeks
Placebo + MTX 88 51 (19.0–75.0)b 8.9 (0.8–35.0)b 2.5 (1.4) 19 24 64 72
IFX IV 3 mg/kg each 8 weeks + MTX 86 56 (25.0–74.0)b 8.4 (0.7–45.0)b 2.8 (1.5) 19 32 63 79
IFX IV 3 mg/kg each 4 weeks + MTX 86 51 (19.0–78.0)b 7.2 (0.5–33.8)b 2.6 (1.5) 20 31 53 76
IFX IV 10 mg/kg each 8 weeks + MTX 87 55 (19.0–80.0)b 9.0 (0.5–49.9)b 2.5 (1.4) 20 30 57 77
IFX IV 10 mg/kg each 4 weeks + MTX 81 52 (23.0–74.0)b 8.7 (0.6–47.0)b 2.5 (1.3) 23 35 65 68
ASPIRE27 – 52 weeks
Placebo + MTX 282 50 (13) 0.9 (0.7) NI 22 (11) 34 (15) 38 82
IFX IV 3 mg/kg each 8 weeks + MTX 359 51 (12) 0.8 (0.7) NI 21 (10) 32 (15) 37 85
IFX IV 6 mg/kg each 8 weeks + MTX 363 50 (13) 0.9 (0.8) NI 22 (11) 33 (15) 39 82
START34 – 22 weeks
Placebo + MTX 363 52.0 (44–61)b 8.4 (4–15)b NI 15 (10–21)b 22 (15–32)b 59.2b 39.4b
IFX IV 3 mg/kg each 8 weeks + MTX 360 53.0 (45–61)b 7.8 (3–15)b NI 15(11–21)b 22 (15–31)b 59.2b 43.3b
IFX IV 10 mg/kg each 8 weeks + MTX 361 52.0 (43–60)b 6.3 (3–14)b NI 15 (10–21)b 22 (15–30)b 59.0b 41.3b
Abe et al.32 – 14 weeks
Placebo + MTX 47 55.1 (7.6) 7.5 (5.0) NI 13.5 (7.6) 17.8 (8.7) 89.4 95.7
IFX IV 3 mg/kg each 8 weeks + MTX 49 55.2 (10.9) 9.1 (7.4) NI 15.1 (9.0) 19.0 (11.8) 85.7 89.8
IFX IV 10 mg/kg each 8 weeks + MTX 51 56.8 (10.5) 7.1 (5.1) NI 13.2 (6.2) 18.7 (12.3) 92.2 94.1
Zhang et al.29 – 18 weeks
Placebo + MTX 86 48.9 (8.0) 96.0 (74.6)c NI NI NI NI NI
IFX IV 3 mg/kg + MTX 87 47.9 (10.1) 85.6 (74.0)c NI NI NI NI NI
Durez et al.30 – 52 weeks
Placebo + MTX 14 53.8 (15.2) 0.45 (0.29) NI 10.3 (5.5) 11.6 (7.5) NI 0
IFX IV 3 mg/kg each 8 weeks + MTX 15 50.0 (9.9) 0.36 (0.31) NI 12.5 (5.4) 15.9 (8.0) NI 0
ATTEST28 52 weeks
Placebo + MTX 110 49.4 (11.5) 8.4 (8.6) NI 20.1 (7.0) 30.3 (11.7) 70.0 84.5
IFX IV 3 mg/kg + MTXa 165 49.1 (12.0) 7.3 (6.2) NI 20.3 (8.0) 31.7 (14.5) 71.5 86.1
SWEFOT3,31 – 104 weeks
SSZ 1000 mg bid + HCQ 400 mg/day + MTX 130 52.9 (13.9) 6.3 (3.6)c NI NI NI 8 NI
IFX IV 3 mg/kg each 8 weeks + MTX 128 51.1 (13.3) 6.2 (3.5)c NI NI NI 6 NI
NSAID, nonsteroidal anti-inﬂammatory drugs; IFX, inﬂiximab; HCQ, hydroxychloroquine; MTX, methotrexate; SSZ, sulfasalazine; DMARD, disease-modifying anti-rheumatic drug; IV, intravenously;
SD, standard deviation; BID, twice a day; NI, not informed.
a Inﬂiximab at days 1, 15, 43, 85 and each 56 days.
b Median.
c In months.
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eﬁned active RA as three or more  swollen and eight or more
ender joints in addition to further criteria. Non-steroidal anti-
nﬂammatory drugs (NSAIDs) at stable doses and low doses of
ral glucocorticoid (≤10 mg/day prednisolone) were allowed in
ll trials except in Durez et al.30 This study30 and SWEFOT31
valuated only patients with initial RA, deﬁned as disease
uration of less than 12 months. The ASPIRE27 and Durez
t al.30 studies evaluated MTX-naive patients, but the other
tudies evaluated patients with insufﬁcient responses to MTX.
he mean weekly dose of MTX  was 7.2 ± 2.0 mg in Abe et al.,32
.5 mg  in Maini et al.33 and ranged from 7.5 to 20 mg  in Durez
t al.30 and Zhang29 studies. MTX  dose ranged from 15 to 20 mg
n the other studies.3,27,28,31,34–36
ethodological  quality  and  risk  of  bias
ine trials were classiﬁed as randomised, but only two of
hese studies reported the methods of randomisation.27,35
he Jadad scale score was generally good (ranging from
oderate to high). The pharmaceutical industry funded six
tudies.27,28,30,31,34,35 We identiﬁed a potential source of bias
n three trials,30,31,33 and only one study35 was classiﬁed as
ow risk of bias (Table 2).
CR  response
nﬂiximab  standard  dose  (3  mg/kg  every  eight  weeks)  per
ollow-up  period
leven studies were included in this analysis. Six of them
ncluded 1470 patients and presented results of up to 30
eeks of follow-up,28–30,32,34,35 four studies with 1086 patients
resented results of 52 weeks27,30,31,36 and one study of
58 patients presented results of 104 weeks.3 Patients who
eceived combination therapy with IFX showed a better
CR response than patients treated with MTX alone or in
ombination with DMARDs until 30 and 52 weeks of treat-
ent. However, no signiﬁcant difference between groups was
bserved after 104 weeks of follow-up. The heterogeneity of
CR20 and ACR50 was signiﬁcant and moderate for the 30
eeks of follow-up studies (Table 3). Heterogeneity at 52 weeks
f follow-up was assessed using the stratiﬁcation between
TX-naive patients and patients with insufﬁcient responses
o MTX  (see Section “Heterogeneity assessment and subgroup
nalysis”).
nﬂiximab  standard  dose  per  patient  proﬁle
he patient’s previous treatments, regardless of follow-up
eriod, revealed that the IFX + MTX  combination achieved
etter results than synthetic DMARDs in patients who had
reviously failed to MTX  treatment, compared to MTX-naïve
atients (Table 3).
nﬂiximab  standard  dose  according  to  disease  duration
ombination therapy with IFX showed better ACR responses
han MTX  alone or in combination with synthetic DMARDs in
atients with established RA. This result was not observed in
atients with early RA (Table 3). 5;5 5(2):146–158 151
High-dose  inﬂiximab
Patients that used IFX regimens with doses higher than
3 mg/kg or in shorter intervals showed better ACR responses
than patients treated with MTX alone or in combination. Meta-
analysis of high-dose IFX versus standard dose of 3 mg/kg
every eight weeks did not show difference in ACR20 and ACR50
outcomes within 54 weeks of follow-up. Despite being statis-
tically signiﬁcant, difference in ACR70 response was boarder
line favouring IFX high-doses (Table 3).
Clinical  remission
Two studies assessed clinical remission at 2828,34 and 54 weeks
of follow-up27,30 in patients using the standard dose of IFX.
Meta-analysis favoured IFX + MTX combination in all follow-
up periods and in the overall analysis, with no statistically
signiﬁcant heterogeneity observed. The RR up to 28 weeks of
treatment was 2.57 ([1.44; 4.60]; I2 = 30%; p = 0.23). The RR at 52
weeks was 1.48 ([1.07; 2.05]; I2 = 0%; p = 0.62), and the overall
analysis, which assessed 1569 patients, produced an RR = 1.92
([1.35; 2.74]; I2 = 49%; p = 0.12).
Radiographic  progression
A meta-analysis of three studies3,27,36 revealed lower radio-
graphic progression in patients who were treated with
IFX + MTX at a standard dose than in patients who  were
treated with other synthetic DMARDs at 52 and 104 weeks. Sta-
tistically signiﬁcant differences were observed in patients with
an insufﬁcient response to MTX and treatment-naive patients
(Fig. 2).
Withdrawals
A meta-analysis of ﬁve studies,3,27,28,32,36 comprising 1474
patients, revealed a lower risk of withdrawals due to
lack of efﬁcacy in the group treated with IFX + MTX
(RR = 0.33 [0.17; 0.63]; I2 = 45%; p = 0.12). Meta-analysis of eight
studies,3,27–30,32,34,36 which assessed 2399 patients, revealed
no difference between groups in withdrawals due to adverse
events (RR = 1.59 [0.96, 2.65]; I2 = 40%; p = 0.11). After removal of
SWEFOT3 study, in which the control group included patients
who received HCQ and SSZ in combination with MTX,  the over-
all risk of withdrawals due to adverse events was higher in the
IFX + MTX group (RR = 2.05 [1.33; 3.16]; I2 = 0%; p = 0.43). Anal-
ysis of withdrawals due to adverse events by patient proﬁle
revealed an increased risk for MTX-naive patients (RR = 3.01
[1.49; 6.06]; I2 = 0%; p = 0.97) but not in patients with an insufﬁ-
cient response to MTX. Regimens with high-dose IFX were as
safe as the standard regimen regarding discontinuation due
to adverse events (RR = 1.12 [0.80; 1.57]).
Safety
Safety meta-analyses revealed no statistically signiﬁcant dif-
ferences between the IFX standard dose + MTX  and DMARD
groups in the outcomes of infection, serious infections, seri-
ous adverse events, tumours and death. Infusion reactions
occurred more  frequently in the IFX + MTX group (RR = 2.21
[1.63; 2.99]). However, serious infections and infusion reactions
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IFX + MTX
Study or subgroupa
b
c
3.1.2 MTX-naive
Total (95% IC)
Test for overall effect: z = 5.71 (P=.00001)
Test for subqoup differences: Chi2 = 0.77, df =1 (P=.38); I2 = 0%
Total (95% IC)
Test for overall effect: z = 4.68 (P<.00001)
Test for subqroup differences: Chi2 = 0.01. df = 1 (P=.91); I2 = 0%
Test for subqroup differences: Chi2 = 4.39, df = 1 (P=.04); I2 = 77.2%
Total (95% IC)
Test for overall effect: z = 2.14 (P=.03)
3.1.1 Insufficient responses to MTX
3.2.1 Insufficient responses to MTX
3.2.2 MTX-naive
3.3.2 Virgens para MTX
ATTRACT [35]
SWEFOT [3]
Subtotal (95% IC)
ATTRACT [35]
SWEFOT [3]
Subtotal (95% IC)
ATTRACT [35]
SWEFOT [3]
Subtotal (95% IC)
1.3
4
0.2
1.29
0.3
1.1
2.79
0.1 1.6 0.6 2.1
4.4
2.79
71
 106
177
64
109
173
25.2%
19.5%
44.7%
–1.80 [–3.25, –0.35]
–1.66 [–3.45, –0.13]
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Fig. 2 – Meta-analysis of radiological progression according to the Van der Heijde modiﬁed Sharp score 2a –Total Score; 2b –
Erosion score; 2c- Joint-space narrowing.
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Table 2 – Within-study quality and risk of bias assessment.
Study Modiﬁed  Jadad  scale Risk  of bias
Randomisation  Appropriate
randomisation
method
Inappropriate
randomisation
method
Concealment  Appropriate
Concealment
method
Losses  to
follow-up
ITT
analysis
Score  Sequence
generation
Allocation
concealment
Blinding  of  participants
and  personnel
Blinding  of
outcome
assessment
Incomplete
outcome  data
Selective
outcome
reporting
Overall  risk
of bias
ATTRACT35,36 1 1 0 1 1  1 1 6 L  L  L  L  L L L
Maini et  al.33 1 0 0 1 1  1 1 5 U L  L  L  L H  H
ASPIRE27 1 1 0 1 1  1 0 5 L  L  L  L  U L U
START34 1 0 0 1 1  1 1 5 U U L  L  L L U
ATTEST28 1 0 0 1 1  1 1 5 U U L  L  L L U
Zhang 29 1 0 0 1 0  1 1 4 U U U U L U U
SWEFOT3,31 1 1 0 0 0  1 1 4 U H H H  L L H
Abe et  al.32 1 0 0 0 0  1 1 3 U U U U L L U
Durez et  al.30 1 0 0 0 0  1 1 3 U U H L  L L H
U, unclear risk of bias; L, low risk of bias; H, high risk of bias.
Table 3 – Meta-analysis of the efﬁcacy of inﬂiximab compared to control.
Comparison [study] ACR 20 (RR, 95% CI) I2 (%)a p-Valueb ACR 50 (RR, 95% CI) I2 (%)a p-Valueb ACR 70 (RR, 95% CI) I2 (%)b p-Valueb
Inﬂiximab standard dose according time to follow up
30 weeks28–30,32,34,35 1.99 (1.56; 2.55) 68 0.009 2.45 (1.73; 3.48) 54 0.05 2.64 (1.78; 3.91) 12 0.34
52 weeks 27,30,31,36 1.48 (1.11; 1.96) 70 0.02 1.47 (1.25; 1.74) 0 0.49 1.66 (1.31; 2.09) 0 0.48
104 weeks3 1.20 (0.87; 1.67) – – 1.38 (0.90; 2.10) – – 1.18 (0.66; 2.12) –  –
Inﬂiximab standard dose per patient proﬁle
Insufﬁcient responses to MTX3,28,29,32,34,36 1.77 (1.38; 2.26) 74 0.002 2.13 (1.53; 2.97) 61 0.003 2.18 (1.43; 3.34) 43 0.12
MTX-naive27,30 1.40 (0.84; 2.34) 64 0.10 1.44 (1.18; 1.76) 0 0.51 1.56 (1.19; 2.04) 0 0.58
Inﬂiximab standard dose according to disease duration
Early RA, disease duration < 1 year3,30 1.45 (0.89; 2.36) 51 0.15 1.47 (1.02; 2.14) 0 0.15 1.30 (0.76; 2.23) 0 0.40
Established or late RA, disease duration > 1
year27–29,32,34,36
1.75 (1.30; 2.34) 87 <0.00001 2.11 (1.48; 3.01) 74 0.002 2.18 (1.50; 3.15) 45 0.10
Inﬂiximab high doses
Doses higher than 3 mg/kg each 8 weeks
versus DMARD27,32,34,36
2.41 (1.56; 3.73) 92 <0.00001 3.46 (2.01; 5.96) 85 <0.00001 4.56 (2.20; 9.46) 75 =0.001
High doses versus standard dose IFX27,32,34,36 1.07 (0.97; 1.17) 22 0.28 1.17 (1.00; 1.36) 27 0.25 1.19 (1.01; 1.41) 0 0.46
CI, conﬁdence interval; DMARD, disease-modifying anti-rheumatic drug; IFX, inﬂiximab; RA, rheumatoid arthritis; RR, relative risk; –, not estimable.
a I2 > 40% indicate heterogeneity between studies.
b p-Value < 0.10 of 2 indicates heterogeneity between studies.1
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showed moderate heterogeneity. Subgroup analysis revealed
that MTX-naive patients who  received IFX + MTX had more
serious infections than the MTX  group (2.80 [1.14; 6.84]). Still,
this result was obtained from a single study27 (Table 4).
Regimens with high-dose IFX were as safe as the standard
regimen regarding serious adverse events (1.15 [0.77; 1.71]) and
serious infections (1.84 [0.71, 4.79]). However, the heterogene-
ity of serious infections was moderate and signiﬁcant (68%;
0.04), the study ASPIRE27 being the source of this heterogene-
ity. The risk of serious infections became higher in patients
who  received high-dose IFX than patients who received the
standard IFX dose when the ASPIRE study was excluded,
and no signiﬁcant heterogeneity was observed (RR = 3.07 [1.42;
6.64]).
Heterogeneity  assessment  and  subgroup  analysis
The heterogeneity of ACR20 and ACR50 was signiﬁcant and
moderate for the studies with up to 30 weeks of follow-
up (Table 3). Heterogeneity became non-signiﬁcant and the
results remained favourable to IFX + MTX  (1.74 [1.32; 2.29])
when the ATTRACT35 and START34 studies were excluded from
the ACR20 meta-analysis of 30 weeks. Heterogeneity became
non-signiﬁcant and the results still favoured the group receiv-
ing IFX + MTX  (1.74 [1. 32; 2.29]) when the START study34 was
excluded from the ACR50 meta-analysis of 30 weeks. No rea-
sonable explanation for the source of heterogeneity could be
established. The cause of heterogeneity of ACR analysis at 52
weeks was the difference in patient proﬁle with respect to
previous experience with DMARs. Therefore, we conducted
a subgroup analysis, in which ACR20 showed no statistical
signiﬁcance between the groups who received IFX + MTX or
DMARDs in patients with an insufﬁcient response to MTX
(1.72 [0.92; 3.22]) and in MTX-naive patients (RR = 1.40 [0.84;
2.34]). For ACR50, IFX + MTX  regimen was superior in MTX-
naive patients (1.44 [1.18; 1.76]) but not in patients who had
an insufﬁcient response to MTX  (1.72 [0.98; 3.00]). In con-
trast, IFX + MTX  was statistically superior to DMARD therapy
in MTX-naive patients (1.56 [1.19; 2.04]) and in patients with
an insufﬁcient response to MTX  (2.20 [1.06; 4.56]) in ACR70
meta-analysis.
Discussion
This systematic review and meta-analysis included nine ran-
domised controlled clinical trials and one ongoing study, and
showed superior results of efﬁcacy as evaluated by ACR and
DAS28, and of radiographic progression for IFX + MTX com-
pared to MTX  monotherapy or in combination with other
DMARDs, regardless of disease duration, dose and patient pro-
ﬁle.
The efﬁcacy of the IFX + MTX  regimen was assessed from 14
weeks of treatment32 to 104 weeks3 in patients with an insuf-
ﬁcient response to MTX  and in MTX-naive patients. IFX + MTX
30,31use began early after RA diagnosis or after 10 years of
disease duration32,35,36 on average. The therapeutic regimen
was variable and included the administration of 3 or 10 mg/kg
IFX every four or eight weeks33,35,36 or 6 mg/kg IFX every eight 0 1 5;5 5(2):146–158
weeks.27 The control group included placebo + MTX  or a com-
bination of synthetic DMARDs.
These differences affected the size and direction of the
effect, which favoured IFX + MTX especially during shorter
periods of follow-up in patients with established RA and
an insufﬁcient response to MTX. These results support the
treatment with synthetic DMARDs, reserving the IFX + MTX
regimen for cases of a failure of the ﬁrst-line regimen. This
approach is corroborated by Du Pan et al.,37 who  performed
a systematic review that speciﬁcally evaluated patients with
early RA and recommended the use of IFX + MTX for cases with
rapid radiographic progression, insufﬁcient response to MTX
or other clinical and biological signs of aggressive disease,
since there is no robust evidence that supports the efﬁcacy,
safety and cost of the early use of IFX.
The results of efﬁcacy and safety also encourage the use of
the recommended standard regimen of 3 mg/kg IFX at weeks 0,
2 and 6 and then every eight weeks in combination with MTX,
instead of increased dose or shorter intervals of IFX adminis-
tration, as described in individual studies.4,7
Clinical remission favoured the use of IFX + MTX  after 24
and 54 weeks of treatment and the ACR response after 52
weeks. However, the high heterogeneity of the analysis of
ACR20 and ACR50 for up to 30 weeks of treatment and the
lack of effect of ACR20 at 52 weeks in the subgroup analy-
sis by past DMARD exposure were notable. Wiens et al.18 also
reported inconsistent results in the ACR20 and 50 responses
after 30 weeks, and considered the high number of patients
who achieved the therapeutic response in the test and con-
trol groups on the START34 study as a possible explanation.
The ACR20 response may be more  sensitive to the use of
some treatments because it is less strict. However, differences
between treatments became more  evident with more  strict
ACR responses because in this case these responses were
directly related to the efﬁcacy of the biological agent use.
Furthermore, only the SWEFOT study3,31 assessed efﬁ-
cacy outcomes for up to 104 weeks of follow-up, and this
study reported no difference in the ACR responses between
IFX + MTX and DMARD combination groups. This affected
also the meta-analysis of our study, because when it was
excluded the result of efﬁcacy outcomes was favourable for
the IFX + MTX. In contrast, the prevention of radiographic pro-
gression using IFX + MTX was conﬁrmed, despite the control
group (i.e., with DMARD combination or MTX  monotherapy).
Withdrawals due to adverse events were especially affected
by the exclusion of the SWEFOT study.3,31 With the exclu-
sion of this study the analysis became statistically signiﬁcant
favouring IFX + MTX. This result was expected because the
addition of a higher number of drugs to a therapeutic regimen
increases the probability of adverse events and decreases the
differences between strategies. Other systematic reviews that
did not include this study also reported a greater loss to follow-
up as a result of adverse events in the IFX + MTX  group.16,18
Considering withdraw due to adverse events according to
patients’ past experience with DMARDs, the results of our
meta-analysis showed higher risk of loss in the IFX + MTX
group for MTX-naive patients, but not for patients with an
insufﬁcient response to MTX, as reported by Chen et al.15
These results suggest that previously treated patients exhibit
a higher tolerance to adverse events.
r e v b r a s r e u m a t o l . 2 0 1 5;5 5(2):146–158 155
Table 4 – Safety meta-analysis of standard dose IFX 3 mg/kg each 8 weeks.
Outcome Number of
evaluated studies
[study]
Patients (n) RR (IC 95%) I2a p-Valueb
Infections 4 658 1.04 (0.73; 1.47) 66% 0.03
Insufﬁcient responses to MTX 33,28,32 629 1.21 (0.75; 1.98) 57% 0.10
MTX-naïve patients 130 29 0.81 (0.61; 1.06) – –
Serious infections 6 2128 1.19 (0.48; 2.93) 56% 0.08
Insufﬁcient responses to MTX 43,28,34,36 1428 0.83 (0.33; 2.06) 31% 0.24
MTX-naïve patients 227,30 700 2.80 (1.14; 6.84) – –
Serious adverse events 8 2397 1.02 (0.79; 1.33) 0% 0.57
Insufﬁcient responses to MTX 63,28,29,32,34,36 1697 0.86 (0.61; 1.21) 0%  0.57
MTX-naïve patients 227,30 700 1.32 (0.87; 1.98) 0% 0.63
Tumours 7 2369 1.87 (0.42; 8.35) 0% 0.92
Insufﬁcient responses to MTX 63,28,29,32,34,35 1698 1.87 (0.42; 8.35) 0% 0.92
MTX-naïve patients 127 671 – – –
Tuberculose 5 1928 4.12 (0.47; 36.07) 0% 0.78
Insufﬁcient responses to MTX 428,29,32,34 1265 2.97 (0.12; 71.81) – –
MTX-naïve patients 127 663 5.48 (0.28; 105.67) – –
Death 6 2052 1.05 (0.20; 5.42) 0% 0.55
Insufﬁcient responses to MTX 43,28,32,34 1352 2.47 (0.26; 23.61) 0% 0.86
MTX-naïve patients 227,30 700 0.40 (0.04; 4.38) – –
Infusion reactions 3 1042 2.21 (1.63; 2.99) 72% 0.03
Insufﬁcient responses to MTX 228,32 371 1.52 (1.02; 2.26) 0%  0.40
MTX-naïve patients 127 671 3.16 (1.98; 5.03) – –
CI, conﬁdence intervals; RR, relative risk; MTX, methotrexate; –, not estimable.
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b p-Value < 0.10 of 2 indicates heterogeneity between studies.
No differences in safety were observed in this or previ-
us systematic reviews,15,18,19 but other evidence sources have
eported that the use of anti-TNF increases patients’ risk
f developing tuberculosis (TB) and other infections.38–40 An
valuation of the biological products database of the Spanish
ociety of Rheumatology revealed incidence rates of 1113 per
00,000 in 2001, which was signiﬁcantly higher than national
ates.38 A meta-analysis of safety from observational studies40
elated an increased risk of infections of approximately 40%
or RA patients who were treated with anti-TNF (RR = 1.37
1.18; 1.60]). These risks support the use of TB screening for all
atients who might receive anti-TNF treatment, and these
atients should be followed using new tests for the signals
nd symptoms of infections, especially during the ﬁrst year of
reatment.7,41
Regarding the comparison of high-dose IFX and the
tandard dose of 3 mg/kg every 8 weeks, we  did not ﬁnd signiﬁ-
ant differences in ACR outcomes after 54 weeks of follow-up.
herefore, the lower dose of 3 mg/kg IFX every eight weeks
as as effective as the other doses in isolated studies32,34,35
nd in the meta-analysis of this review. However, the results
f the meta-analysis on serious infections showed signiﬁcant
eterogeneity. The ASPIRE27 study, which included MTX-naive
atients, was excluded, and the risk of infections became
igher with high doses of IFX + MTX, showing that MTX-naive
atients may be more  susceptible to infections. Therefore,
he group that received high doses of IFX had high infec-
ion rates compared to the standard dose IFX group. These
esults were consistent with Aaltonen et al.19 and Alonso-Ruizet al.16 who reported no differences in efﬁcacy between high
and standard doses of IFX. However, no difference in safety
between the dose regimens was described,19 although this
study did not analyse heterogeneity or perform a subgroup
analysis by patient DMARD exposure. An IFX induction reg-
imen using 10 mg/kg is not indicated by the manufacturer,
and it is discouraged by the results of clinical trials and this
systematic review, since it provides no additional beneﬁts.
Besides, this strategy can increase the risk of infections com-
pared to placebo + MTX group.34,35
One RCT that was not included in our systematic review
because of the dose escalation analysed the increase in IFX
dose from 3 to 5 mg/kg every 8 weeks and revealed no addi-
tional beneﬁt to the primary outcome (DAS28 after 28 weeks)
or secondary outcomes (e.g., number of swollen and ten-
der joints, C-reactive protein and erythrocyte sedimentation
rate) within 52 weeks. Furthermore, an increase in the inci-
dence of adverse events was observed, but these adverse
events did not include serious adverse events or serious
infections.42
Ollendorf et al.43 also demonstrated that patients using IFX
increased the dose more  frequently over shorter periods of
time than patients using etanercept and adalimumab (32.1%,
8.5% and 4.7%, respectively). Consequently, the cost of IFX
treatment was approximately 30% higher than other anti-
TNF agents. These results suggest that increasing IFX dose
in patients who do not adequately respond to the standard
dose of 3 mg/kg IFX every eight weeks in combination with
MTX  is not the best strategy.42,44
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Limitations
A random effects model was used, and the results of the
subgroup analyses lost part of its inference value due to the
clinical heterogeneity of trials in the evaluated outcomes,
patient proﬁle, period of follow-up, dose and administration
period. However, the results were consistent with the lit-
erature, and although not entirely reﬂective of reality, they
demonstrate the direction of the effect. Other limitation is
that only three of the published RCTs were not funded by
the pharmaceutical industry. Studies funded by the pharma-
ceutical industry are more  likely to report favouring outcomes
to their products45 and therefore, the results of these studies
should be interpreted cautiously. Because of that, the assess-
ment of risk of bias became more  pertinent, and only one study
in this review was classiﬁed as a low-risk of bias in all assessed
domains. Also, we  could not assess the publication bias of the
outcomes because the recommended number of clinical trials
to perform this analysis with robustness is 10 studies. How-
ever, we  conducted the manual search and search through
the grey literature to minimise this effect. Evidence on the
IFX + MTX  regimen versus MTX  is well established, but other
types of comparison must be explored. Only one published
study3,31 assessed the regimen INF + MTX  versus a DMARD
combination. Because of that, this systematic review could not
establish the best strategy for patients in whom ﬁrst-line ther-
apy fails. Clinical trials that compare the efﬁcacy of IFX + MTX
to combinations of DMARDs are required to cover this knowl-
edge gap.
Implications  for  clinical  practice
The use of IFX + MTX  promoted radiographic and clinical ben-
eﬁts that were less signiﬁcant in early RA patients, which
suggests that early treatment with any synthetic DMARD is
more important than early treatment using a biological agent.
The combination of IFX + MTX  may be a better strategy for the
prevention of radiographic progression than MTX alone. The
choice between INF + MTX  over combination DMARDs should
consider their ability to reduce functional loss over time (i.e.,
radiographic progression) balanced with the small clinical dif-
ferences that are observed over long periods of follow-up, and
the higher cost of anti-TNF treatment.
Conclusions
IFX + MTX  therapeutic regimens showed better results of
clinical efﬁcacy evaluated by ACR and DAS28 than MTX
monotherapy or combined DMARDs, regardless of disease
duration, dose and patient past experience with DMARD. The
efﬁcacy of IFX + MTX  was more  evident in shorter periods
of follow-up, patients with established RA and patients with
insufﬁcient response to MTX. Radiographic progression was
averted in longer follow-up periods. The lowest dose, 3 mg/kg
IFX every eight weeks, was as effective as the other IFX doses.
The data on safety suggest that increases in IFX doses were
related to an increased incidence of infections, and therefore
should not be used. 0 1 5;5 5(2):146–158
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